Valuation: Allergy Therapeutics plc

Market Cap 348M 470M 407M 380M 655M 44.73B 665M 4.45B 1.75B 22.42B 1.76B 1.73B 74.12B P/E 2026 *
-6.04x
P/E 2027 * -
Enterprise Value 392M 530M 458M 428M 738M 50.41B 750M 5.02B 1.97B 25.27B 1.99B 1.95B 83.53B EV / Sales 2026 *
6.55x
EV / Sales 2027 * -
Free-Float
11.51%
Yield 2026 *
-
Yield 2027 * -
1 day+4.76%
1 week-8.03%
Current month-8.03%
1 month-16.67%
3 months-46.34%
6 months-49.54%
Current year-50.00%
1 week 5
Extreme 5
6.26
1 month 5
Extreme 5
7.5
Current year 5
Extreme 5
12.1
1 year 5
Extreme 5
12.1
3 years 1.2
Extreme 1.2
12.1
5 years 0.8
Extreme 0.8
40.5
10 years 0.8
Extreme 0.8
40.5
Manager TitleAgeSince
Chief Executive Officer 62 2009-08-31
Director of Finance/CFO - 2023-08-10
Corporate Officer/Principal - 2013-04-30
Director TitleAgeSince
Director/Board Member 62 2009-08-31
Chairman 75 2011-01-03
Director/Board Member 69 2017-06-05
Date Insider Type Main position Quantity % Market Cap.
6/13/26 Free

Chief Financial Officer

2,300,000 0.0363%
3/12/26
ZQ Capital Ltd.
SellCompany 1,840,000 0.0300%
3/12/26
ZQ Capital Ltd.
OthersCompany 1,993,473,455 32.4594%
Change 5-day change 1-year change 3-year change Capi.($)
+4.76%-8.03%-35.29%+52.78% 470M
+1.59%+2.85%+40.11%+1.24% 78.32B
-0.84%+0.09%+20.92%+179.15% 49.18B
+2.77%+4.78%-1.65%+27.62% 51.1B
-0.13%+7.42%-50.22%-49.58% 44.71B
+0.80%+2.46%+62.77%-23.33% 30.72B
+1.84%+0.87%+54.17%+85.73% 24.44B
+9.86%+7.94%+122.36%-41.53% 23.62B
+4.29%+9.40%+3.77%+226.51% 21.05B
+1.66%-3.70%+65.40%+123.91% 16.61B
Average +2.66%+1.66%+28.23%+58.25% 34.02B
Weighted average by Cap. +1.89%+3.28%+26.84%+45.11%

Financials

2026 *2027 *
Net sales 59.9M 80.83M 69.92M 65.3M 113M 7.69B 114M 766M 301M 3.86B 304M 297M 12.75B -
Net income -55.7M -75.17M -65.02M -60.72M -105M -7.15B -106M -712M -280M -3.59B -282M -276M -11.85B -
Net Debt 44.2M 59.65M 51.6M 48.18M 83.13M 5.68B 84.45M 565M 222M 2.85B 224M 219M 9.41B -
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Date Price Change Volume
26-08-07 GBX 5.500 +4.76% 121,750
26-08-06 GBX 5.250 +5.00% 1,058,001
26-08-05 GBX 5.000 -4.76% 132,799
26-08-04 GBX 5.250 -7.89% 41,947
26-08-03 GBX 5.700 -4.68% 55,734
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0550GBP
Average target price
0.1300GBP
Spread / Average Target
+136.36%

Annual profits - Rate of surprise